Cellyan Biotechnology Co., Ltd, a Nasdaq-listed biotech supply chain and distribution service provider, reported a sharp 34% revenue decline in fiscal 2026 driven by weakening demand and intensified competition. The company’s core business—OTC pharmaceutical cross-border e-commerce supply chain services—contracted significantly alongside strategic pruning of low-margin customers in its procurement and distribution segment. Concurrently, Cellyan faces ongoing Nasdaq listing compliance challenges after failing to regain the minimum bid price, posing financial and reputational risks. Operating in the highly regulated Hong Kong-Mainland China OTC pharmaceutical niche, Cellyan’s growth will depend on navigating regulatory complexity, optimizing customer mix, and improving operational efficiencies amid volatile market dynamics.